SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Clene Inc. (CLNN) News

Follow Clene Inc. (CLNN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 18 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol CLNN Asset equity Sector Markets 90 days 15 Last 3.49 Updated Nov 04, 2026, 01:43 PM UTC Open live news feed Open CLNN chart & news
M Clene Reports Third-Quarter Revenue of $56,000 EQUITY | Nov 04, 2026, 01:43 PM UTC M Clene Reports $3.9M Q3 Net Income, Cash Runway Through Mid-Q1 2027 Clene reported Q3 2026 net income of $3.9 million, compared with an $8.8 million net loss a year earlier. Cash stood at $9.9 million on Sept. 30, 2026; the company expects its runway to extend through mid-Q1 2027. EARNINGS | Nov 04, 2026, 01:41 PM UTC M Clene Posts Q3 Profit on Warrant Liability Gains EQUITY | Nov 04, 2026, 01:37 PM UTC M Clene Swings to Q3 Net Profit of $3.92 Million EQUITY | Nov 04, 2026, 01:37 PM UTC M Clene Reports Q3 Pretax Profit of USD 3.915 Million EQUITY | Nov 04, 2026, 01:32 PM UTC M Clene Reports Third-Quarter 2026 Financial Results and Operating Highlights Clene said it submitted a New Drug Application to the FDA in October; the supplied body is truncated and does not provide further financial results. EQUITY | Nov 04, 2026, 01:31 PM UTC L Clene reports third-quarter net income of $3.92 million EARNINGS | Nov 04, 2026, 01:31 PM UTC L Clene submits CNM-Au8 new drug application to FDA for ALS Clene announced submission of a new drug application to the FDA for CNM-Au8, intended to treat ALS. REGULATION | Oct 19, 2026, 12:00 PM UTC L CLNN - Clene to Present at Upcoming Investor Conferences CLNN - Clene to Present at Upcoming Investor Conferences NEWS | Sep 22, 2026, 12:00 PM UTC L CLNN - Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA CLNN - Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA REGULATION | Sep 21, 2026, 12:30 PM UTC L CLNN - Clene Announces $4 Million Registered Direct Offering CLNN - Clene Announces $4 Million Registered Direct Offering NEWS | Sep 15, 2026, 01:01 PM UTC M CLNN oral nanotherapeutic for ALS nears NDA submission CLNN is advancing an oral nanotherapeutic for ALS, citing consistent neurofilament reduction and survival benefits in trials. The company says an NDA submission is imminent, with a confirmatory Phase III and targeted com EQUITY | Sep 09, 2026, 02:35 PM UTC L CLNN nears NDA submission for ALS nanotherapeutic CLNN says an ALS nanotherapeutic is nearing NDA submission after clinical survival and neurofilament light benefits, with a strong safety profile. Regulatory review is expected to begin soon, with commercialization targe EQUITY | Sep 09, 2026, 02:05 PM UTC L Clene management to present at September investor conferences Clene Inc. said management will present at the 2026 Cantor Global Healthcare Conference and the H.C. Wainwright 28th Annual Global Investment Conference and host 1x1 investor meetings at both. EQUITY | Sep 03, 2026, 12:07 PM UTC L CLNN - Clene to Present at Upcoming September Investor Conferences CLNN - Clene to Present at Upcoming September Investor Conferences EQUITY | Sep 03, 2026, 12:00 PM UTC L Clene (CLNN) to Present at Emerging Growth Conference Clene (CLNN) says it will present at the Emerging Growth Conference, with no additional details on topics or timing provided in the feed. EQUITY | Aug 17, 2026, 12:30 PM UTC L Clene reports Q2 2026 financial results and operating highlights Clene (CLNN) reports its second quarter 2026 financial results along with recent operating highlights, per the company’s release. EARNINGS | Aug 14, 2026, 12:30 PM UTC L CLNN to present at Canaccord conference CLNN presents at conference EQUITY | Jul 29, 2026, 12:30 PM UTC